{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:04:03Z","timestamp":1784153043877,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,15]]},"DOI":"10.7759\/cureus.112740","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:16:27Z","timestamp":1784150187000},"source":"Crossref","is-referenced-by-count":0,"title":["Durable Complete Response Following Nivolumab Discontinuation in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma Complicated by Bullous Pemphigoid: A Case Report"],"prefix":"10.7759","author":[{"given":"Maria","family":"Abreu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris RL","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, et al.. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016, 375:1856-67. 10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen EEW","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, et al.. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019, 393:156-67. 10.1016\/S0140-6736(18)31999-8","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness B","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, et al.. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019, 394:1915-28. 10.1016\/S0140-6736(19)32591-7","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12907","article-title":"Five-year follow-up of patients with head and neck cancer treated with nivolumab and long-term responders for over two years","volume":"36","author":"Matsuo M","year":"2022","unstructured":"Matsuo M, Yasumatsu R, Masuda M, et al.. Five-year follow-up of patients with head and neck cancer treated with nivolumab and long-term responders for over two years. In Vivo. 2022, 36:1881-6. 10.21873\/invivo.12907","journal-title":"In Vivo"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01050-x","article-title":"Immunotherapy in HPV-related oropharyngeal cancers","volume":"24","author":"Roof L","year":"2023","unstructured":"Roof L, Yilmaz E. Immunotherapy in HPV-related oropharyngeal cancers. Curr Treat Options Oncol. 2023, 24:170-83. 10.1007\/s11864-023-01050-x","journal-title":"Curr Treat Options Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang KK","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, et al.. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010, 363:24-35. 10.1056\/NEJMoa0912217","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142527","article-title":"Progression-free survival and treatment-free interval in head and neck cancer with long-term response to nivolumab: timing of active discontinuation","volume":"16","author":"Matsuo M","year":"2024","unstructured":"Matsuo M, Masuda M, Yamauchi M, et al.. Progression-free survival and treatment-free interval in head and neck cancer with long-term response to nivolumab: timing of active discontinuation. Cancers (Basel). 2024, 16:2527. 10.3390\/cancers16142527","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.1008249","article-title":"Pathogenetic action of viruses in head and neck cancer","author":"Litsou E","year":"2024","unstructured":"Litsou E. Pathogenetic action of viruses in head and neck cancer. Updates in Otorhinolaryngology. IntechOpen, London, UK; 2024. 10.5772\/intechopen.1008249"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103724","article-title":"Evaluation of the attributable fraction and burden of HPV-related oropharyngeal cancers in Greece-the ORPHEAS study","volume":"9","author":"Psyrri A","year":"2024","unstructured":"Psyrri A, Psychogios G, Kyrodimos E, et al.. Evaluation of the attributable fraction and burden of HPV-related oropharyngeal cancers in Greece-the ORPHEAS study. ESMO Open. 2024, 9:103724. 10.1016\/j.esmoop.2024.103724","journal-title":"ESMO Open"},{"key":"ref10","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (2017). Accessed. April 6, 2026: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou X","year":"2020","unstructured":"Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020, 18:87. 10.1186\/s12916-020-01549-2","journal-title":"BMC Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors","volume":"7","author":"Cook S","year":"2024","unstructured":"Cook S, Samuel V, Meyers DE, et al.. Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors. JAMA Netw Open. 2024, 7:e2352302. 10.1001\/jamanetworkopen.2023.52302","journal-title":"JAMA Netw Open"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.1010971","article-title":"Immune cells and their role in immunosuppressive tumor microenvironment of head and neck cancer","author":"Litsou E","year":"2025","unstructured":"Litsou E. Immune cells and their role in immunosuppressive tumor microenvironment of head and neck cancer. Cancer Immunotherapy - Cellular Mechanisms, Therapeutic Advances and Emerging Frontiers. Scheffel TB (ed): IntechOpen, London, UK; 2025. 10.5772\/intechopen.1010971"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/494893-durable-complete-response-following-nivolumab-discontinuation-in-human-papillomavirus-hpv-positive-oropharyngeal-carcinoma-complicated-by-bullous-pemphigoid-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:16:28Z","timestamp":1784150188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/494893-durable-complete-response-following-nivolumab-discontinuation-in-human-papillomavirus-hpv-positive-oropharyngeal-carcinoma-complicated-by-bullous-pemphigoid-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.112740","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}